- Home
- IGMS vs NMS Comparison
IGMS vs NMS Comparison
Compare IGMS & NMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- NMS
- Stock Information
- Founded
- IGMS 1993
- NMS 1993
- Country
- IGMS United States
- NMS United States
- Employees
- IGMS N/A
- NMS N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- NMS Finance Companies
- Sector
- IGMS Health Care
- NMS Finance
- Exchange
- IGMS Nasdaq
- NMS Nasdaq
- Market Cap
- IGMS 82.1M
- NMS 71.8M
- IPO Year
- IGMS 2019
- NMS N/A
- Fundamental
- Price
- IGMS $1.24
- NMS $12.01
- Analyst Decision
- IGMS Hold
- NMS
- Analyst Count
- IGMS 8
- NMS 0
- Target Price
- IGMS $6.14
- NMS N/A
- AVG Volume (30 Days)
- IGMS 198.4K
- NMS 12.0K
- Earning Date
- IGMS 03-06-2025
- NMS 01-01-0001
- Dividend Yield
- IGMS N/A
- NMS 4.11%
- EPS Growth
- IGMS N/A
- NMS N/A
- EPS
- IGMS N/A
- NMS N/A
- Revenue
- IGMS $2,679,000.00
- NMS N/A
- Revenue This Year
- IGMS $134.71
- NMS N/A
- Revenue Next Year
- IGMS $74.27
- NMS N/A
- P/E Ratio
- IGMS N/A
- NMS N/A
- Revenue Growth
- IGMS 25.77
- NMS N/A
- 52 Week Low
- IGMS $1.15
- NMS $9.21
- 52 Week High
- IGMS $22.50
- NMS $12.18
- Technical
- Relative Strength Index (RSI)
- IGMS 37.38
- NMS 25.70
- Support Level
- IGMS $1.17
- NMS $12.09
- Resistance Level
- IGMS $1.31
- NMS $12.27
- Average True Range (ATR)
- IGMS 0.09
- NMS 0.08
- MACD
- IGMS 0.05
- NMS -0.02
- Stochastic Oscillator
- IGMS 32.14
- NMS 12.33
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About NMS Nuveen Minnesota Quality Municipal Income Fund
Nuveen Minnesota Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Minnesota state income taxes and its secondary investment objective is the enhancement of portfolio value.